Blood Coagulation Disorders  >>  Erbitux (cetuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
NCT01524978 / 2011-004426-10: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO 2014
More
Completed
2
208
US, Europe, RoW
cetuximab, vemurafenib, Zelboraf
Hoffmann-La Roche
Multiple Myeloma, Neoplasms
10/16
10/16

Download Options